Navigation Links
SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
Date:9/5/2008

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of a small molecule LFA-1 product candidate for T-cell mediated ophthalmic diseases. Sunesis and SARcode entered into a license agreement providing SARcode with an exclusive license to Sunesis' LFA-1 technology to develop LFA-1 inhibitors in March 2006.

"LFA-1 antagonists mediate both migration and adhesion of the white blood cells to sites of inflammation as part of the body's immune response," said Tom Gadek, Ph.D., chief executive officer of SARcode Corporation. "Lead indications for LFA-1 include dry eye and allergic conjunctivitis, both large indications with unmet medical needs. The results of this study will inform dose selection for several Phase 2 studies to commence in the first half of 2009."

"We congratulate SARcode on the progress they have made moving this program forward into the clinic," said Daniel Swisher, chief executive officer and president of Sunesis. "The LFA-1 inhibitor product candidate, which was discovered at Sunesis, has the potential to address immunological and inflammatory diseases, including dry eye syndrome. We look forward to SARcode's continued advancement of this novel compound."

As part of the license agreement, Sunesis has earned a milestone payment from SARcode of $500,000 and a $375,000 convertible note. The next payable milestone, if earned, will be for initiation of the Phase 2 clinical program.

About SARcode

SARcode is a privately-held biopharmaceutical company focused on the development of best in class small molecule LFA-1 antagonists as novel nonsteroidal immunomodulators/ anti-inflammatory agents for the treatment of T-cell mediated inflammatory diseases.

About Sunesis Pharmaceuticals <
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
2. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
8. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
9. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
10. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... SOUTH PLAINFIELD, N.J. , Aug. 20, 2014 PTC ... it will participate at two upcoming investor conferences: ... Four Seasons Hotel in Boston on ... Annual Biotech Conference at The Mandarin Oriental Boston on Thursday, ... will present a company update at the Bank of America ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... is available in its catalogue: ... Key Trends and Opportunities to 2017 ... Synopsis The report provides in depth ... Canadian personal accident and health insurance segment, ...
(Date:8/20/2014)... 20, 2014 Children aren,t the only ... to help prevent disease. The Centers for Disease ... adults, but currently, many adults are not following ... Immunization Awareness Month, and the American Lung Association ... those with lung disease, to talk with their ...
Breaking Medicine Technology:PTC Therapeutics to Participate at Upcoming Investor Conferences 2Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 2Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 3Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 4Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 5Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 7Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 8Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 9Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 10Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 11Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 12Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 13Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 14Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 15Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 16Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 17Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 18Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 19Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 20Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 21Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 22Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 23American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3
... Jan. 23, 2012   South Florida Radiation Oncology, LLC (SFRO) ... with Mevion Medical Systems to purchase the MEVION S250 ... develop the first proton therapy treatment center in West ... targeted to begin in 2013. South ...
... (B. Braun), a leader in infusion therapy and pain management, ... approval for 2g Cefazolin for Injection USP and Dextrose ... The FDA approval makes B. Braun the first ... and other healthcare settings where it is a frequently prescribed ...
Cached Medicine Technology:South Florida Radiation Oncology to Develop Proton Therapy Center 2B. Braun Becomes the First to Deliver FDA-Approved 2g Cefazolin 2B. Braun Becomes the First to Deliver FDA-Approved 2g Cefazolin 3
(Date:8/20/2014)... -- Pigs, hearts transplanted into baboons survived for more ... previously achieved, researchers report. The work is part ... to shorten transplant waiting lists. In this study, ... abdomens. The genetic engineering and new methods of suppressing ... hearts to survive for more than a year. ...
(Date:8/20/2014)... Dennis Thompson HealthDay Reporter ... help older women avoid a condition that causes a life-threatening ... women had a 10 percent lower risk of developing atrial ... in the Aug. 20 issue of the Journal of ... protection against the heart rhythm disorder even if they were ...
(Date:8/20/2014)... The Board of Directors of top ... is pleased to announce the expansion of its ... and the surrounding region. In support of this ... AIA has relocated to the firm’s office in Shanghai, ... and design and to better support regional clients. ...
(Date:8/20/2014)... to treating kidney failure by removing waste products from ... who suddenly developed the condition, in an analysis led ... Medicine. , Their findings, published online in the journal ... method that is standardly used for people with sudden ... the patient. , "Our findings question the accepted notion ...
(Date:8/20/2014)... 2014 As concerns regarding the health ... ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgery continue to ... from New York are urging the U.S. Food & ... devices. In a letter dated August 19th, Sens. Kirsten ... agency to seriously consider the testimony given during the ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4
... Giving breastfeeding infants of HIV-infected mothers a daily dose ... the risk of HIV transmission to the infants at ... daily for six weeks, according to preliminary clinical trial ... a 75 percent reduction in HIV transmission risk through ...
... , WEDNESDAY, March 2 (HealthDay News) -- Moms-to-be ... oxycodone (Oxycontin) may increase the risk of birth ... report. Taking these types of analgesics just prior to ... to a modest risk of congenital heart defects in an ...
... of Chemistry at Stevens Institute of Technology, recently ... of Michigan. Named in honor of pioneer pharmaceutical ... established to recognize outstanding lifetime achievements in medicinal ... lecture, "Drug Discovery Lessons Learned," was delivered ...
... , WEDNESDAY, March 2 (HealthDay News) -- ... have uncontrolled seizures, drug-related side effects, and a lower ... money, finds a new study. Poor patients also ... appointments with a general practitioner, according to lead author ...
... awarded Arizona State University (ASU) a $1 million grant ... Ph.D., at the Biodesign Institute. The team is working ... a "Cell-CT" scanner, that will perform functional computed tomographic ... will allow researchers to observe and assess the cellular ...
... Amanda Gardner HealthDay Reporter , TUESDAY, March ... or young adult raises your risk of having psychotic ... "This cements much more firmly the reality that ... with the other genetic, environmental and socioeconomic risk factors, ...
Cached Medicine News:Health News:6-month drug regimen cuts HIV risk for breastfeeding infants, NIH study finds 2Health News:6-month drug regimen cuts HIV risk for breastfeeding infants, NIH study finds 3Health News:CDC Links Prescription Painkillers in Pregnancy to Birth Defects 2Health News:Stevens' Dr. A. K. Ganguly receives Topliss Award Lecture from University of Michigan 2Health News:$1 million from W.M. Keck Foundation spurs development of new generation 3-D 'Cell-CT' imaging 2Health News:$1 million from W.M. Keck Foundation spurs development of new generation 3-D 'Cell-CT' imaging 3Health News:Pot Use in Youth Ups Risk of Psychotic Symptoms in Later Life 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: